SCHEMBL953629

SCHEMBL953629

CCOC(=O)c1sc(-c2c(C)nn3ccccc23)nc1-c1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 7/20 0.50
DBF4 Q9UBU7 7/20 0.50
TRPM8 Q7Z2W7 3/20 0.50
ALDH1A1 P00352 5/20 0.46
HSD17B10 Q99714 1/20 0.46
HPGD P15428 3/20 0.45
KDM4E B2RXH2 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
GAA P10253 1/20 0.45
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
PKM P14618 1/20 0.44
MAPK1 P28482 1/20 0.44
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
DHODH Q02127 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL957422 0.92 CDC7 (0.59) CDC7DBF4TRPM8ALDH1A1HSD17B10
SCHEMBL955327 0.87 EGFR (0.46) CDC7DBF4KDM4EKMT2AGAA
SCHEMBL953635 0.87 CDC7 (0.47) CDC7DBF4TRPM8ALDH1A1HSD17B10
SCHEMBL958106 0.86 EGFR (0.45) CDC7DBF4TRPM8ALDH1A1HPGD
SCHEMBL953710 0.86 CDC7 (0.51) CDC7DBF4TRPM8ALDH1A1HSD17B10
SCHEMBL954096 0.84 CDC7 (0.46) CDC7DBF4TRPM8ALDH1A1HSD17B10
SCHEMBL954275 0.83 CDC7 (0.46) CDC7DBF4TRPM8ALDH1A1HSD17B10
SCHEMBL953769 0.83 CDC7 (0.59) CDC7DBF4TRPM8ALDH1A1KDM4E
SCHEMBL953687 0.83 CDC7 (0.61) CDC7DBF4TRPM8ALDH1A1HSD17B10
SCHEMBL952685 0.81 LMNA (0.46) CDC7DBF4TRPM8ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 CDC7 601/4885DBF4 3288/4885TRPM8 2427/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 CDC7 1063/4885DBF4 3779/4885TRPM8 4834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.